One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study

References

• Prentice MB, Rahalison L. Plague. Lancet 2007;369:1196–207. doi:10.1016/S0140-6736(07)60566-2.
   PubMed Web of Science ®Google Scholar
• Williamson ED. Plague. Vaccine 2009;27:D56–60. doi:10.1016/j.vaccine.2009.07.068.
   PubMed Web of Science ®Google Scholar
• Butler T. Plague gives surprises in the first decade of the 21st century in the United States and worldwide. The American journal of tropical medicine and hygiene 2013;89:788–93. doi:10.4269/ajtmh.13-0191.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) Plague.Democratic Republic of the Congo. http://www.who.int/mediacentre/factsheets/fs267/en/
   Google Scholar
• Galimand M, Carniel E, Courvalin P. Resistance of Yersinia pestis to antimicrobial agents. Antimicrobial agents and chemotherapy 2006;50:3233–6. doi:10.1128/AAC.00306-06.
   PubMed Web of Science ®Google Scholar
• Welch TJ, Fricke WF, McDermott PF, White DG, Rosso ML, Rasko DA, et al. Multiple antimicrobial resistance in plague: an emerging public health risk. PloS one 2007;2:e309. doi:10.1371/journal.pone.0000309.
   PubMed Web of Science ®Google Scholar
• Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, et al.. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 2000;283:2281–90.
   PubMed Web of Science ®Google Scholar
• Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert opinion on biological therapy 2004;4:965–73. doi:10.1517/14712598.4.6.965.
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Corbel MJ. Prospects for new plague vaccines. Expert review of vaccines 2009;8:1721–38. doi:10.1586/erv.09.129.
   PubMed Web of Science ®Google Scholar
• Sha J, Kirtley ML, Klages C, Erova TE, Telepnev M, Ponnusamy D, Fitts EC, Baze WB, Sivasubramani SK, Lawrence WS. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates. Clinical and vaccine immunology 2016;23:586–600. doi:10.1128/CVI.00150-16.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei D, Qu Z, Sun L, Miao Y, Yang Y, Lu J, Du W, Wang B, Li B. A safety and immunogenicity study of a novel subunit plague vaccine in cynomolgus macaques. Journal of applied toxicology 2017;14:1–10.
   Google Scholar
• Arnaboldi PM, Sambir M, D'Arco C, Peters LA, Seegers JF, Mayer L, McCormick AA, Dattwyler RJ. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Vaccine 2016;34:5768–76. doi:10.1016/j.vaccine.2016.09.063.
   PubMed Web of Science ®Google Scholar
• Du Y, Rosqvist R, Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infection and immunity 2002;70:1453–60. doi:10.1128/IAI.70.3.1453-1460.2002.
   PubMed Web of Science ®Google Scholar
• Sebbane F, Jarrett C, Gardner D, Long D, Hinnebusch BJ. The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague. Infection and immunity 2009;77:1222–9. doi:10.1128/IAI.00950-08.
   PubMed Web of Science ®Google Scholar
• Weening EH, Cathelyn JS, Kaufman G, Lawrenz MB, Price P, Goldman WE, Miller VL. The dependence of the Yersinia pestis capsule on pathogenesis is influenced by the mouse background. Infection and immunity 2011;79:644–52. doi:10.1128/IAI.00981-10.
   PubMed Web of Science ®Google Scholar
• Anderson DM, Ciletti NA, Lee-Lewis H, Elli D, Segal J, DeBord KL, Overheim KA, Tretiakova M, Brubaker RR, and Schneewind O. Pneumonic plague pathogenesis and immunity in Brown Norway rats. The American journal of pathology 2009;174:910–21. doi:10.2353/ajpath.2009.071168.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Liu Y, Qi Z, Wang W, Kou Z, Zhang Q, Liu G, Liu T, Yang Y, Yang X. Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta. Scandinavian journal of immunology 2010;72:425–33. doi:10.1111/j.1365-3083.2010.02456.x.
   PubMed Web of Science ®Google Scholar
• Chichester JA, Musiychuk K, Farrance CE, Mett V, Lyons J, Yusibov V. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 2009;27:3471–4. doi:10.1016/j.vaccine.2009.01.050.
   PubMed Web of Science ®Google Scholar
• Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, and Irving M. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infection and immunity 2005;73:3598–608. doi:10.1128/IAI.73.6.3598-3608.2005.
   PubMed Web of Science ®Google Scholar
• Chu K, Hu J, Meng F, Li J, Luo L, Xu J, Yuan Z, Li Z, Chen W, Jiao L, et al. Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial. Human vaccines & immunotherapeutics 2016;12:2334–40. doi:10.1080/21645515.2016.1175261.
   PubMed Web of Science ®Google Scholar
• Frey SE, Lottenbach K, Graham I, Anderson E, Bajwa K, May RC, Mizel SB, Graff A, Belshe RB. A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08–0066). Vaccine 2017;35:6759–65. doi:10.1016/j.vaccine.2017.09.070.
   PubMed Web of Science ®Google Scholar
• Chalton DA, Musson JA, Flick-Smith H, Walker N, µgregor A, Lamb HK, Williamson ED, Miller J, Robinson JH, Lakey JH. Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation. Infection and immunity 2006;74:6624–31. doi:10.1128/IAI.00437-06.
   PubMed Web of Science ®Google Scholar
• Nazarova EL., Dyatlov IA, Pozdeev NM, Demyanova VT, Paramonov IV, Rylov AV, Khramov MV, Borzilov AI, Somov AN, Ablamunits VG, AnisimovGeneticmarkersofimmuneresponsetoYersiniapestisF1andVantigens-loadedmicrospheresvaccineagainstplague. Russian Biomedical research 2017;2:19–28.
   Google Scholar
• Roggenkamp A, Geiger AM, Leitritz L, Kessler A, Heesemann J. Passive immunity to infection with Yersinia spp. mediated by antirecombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 1997 65:446–51.
   PubMed Web of Science ®Google Scholar
• Ranjbar R, Afshar D. Development of a loop-mediated isothermal amplification assay for rapid detection of Yersinia enterocolitica via targeting a conserved locus. Iran J Microbiol 2015;7:185–90.
   PubMedGoogle Scholar
• Tomaso H, Mooseder G, Al Dahouk S, Bartling C, Scholz HC, Strauss R, Treu TM, Neubauer H. Seroprevalence of anti-Yersinia antibodies in healthy Austrians. Eur J Epidemiol 2006; 21:77–81. doi:10.1007/s10654-005-5047-z.
   PubMed Web of Science ®Google Scholar